{"id":111025,"date":"2026-07-20T15:08:13","date_gmt":"2026-07-20T15:08:13","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/zealand-pharma-transactions-related-to-share-buy-back-program-week-29-2026\/"},"modified":"2026-07-20T15:08:13","modified_gmt":"2026-07-20T15:08:13","slug":"zealand-pharma-transactions-related-to-share-buy-back-program-week-29-2026","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/zealand-pharma-transactions-related-to-share-buy-back-program-week-29-2026\/","title":{"rendered":"Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)"},"content":{"rendered":"
\n

Company announcement No. 33 \/ 2026<\/p>\n

Zealand Pharma – Transactions related to share buy-back program (week 29, 2026)<\/b><\/p>\n

Copenhagen, Denmark, July 20, 2026<\/b> \u2013 Zealand Pharma A\/S (“the Company” or \u201cZealand Pharma\u201d) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the \u201cProgram\u201d) for week 29 (July 13 – July 17, 2026).<\/p>\n

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596\/2014 (the Market Abuse Regulation, \u201cMAR\u201d) and Commission Delegated Regulation (EU) 2016\/1052 (the \u201cSafe Harbour Regulation\u201d). Reference is made to company announcement no. 15 \/ 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that may be acquired under the Program is 7,152,557, and the Program commenced on May 7, 2026, and will be completed no later than October 31, 2026. The Company has appointed Danske Bank as lead manager for the Program. Danske Bank will make its own trading decisions independently of, and without influence from, the Company.<\/p>\n

Transactions executed in week 29<\/b>
The following transactions have been executed on Nasdaq Copenhagen (XCSE) under the Program during\u00a0week 29 (July 13, 2026 – July 17, 2026):<\/p>\n\n\n\n\n\n\n\n\n\n\n
Date<\/b><\/td>\nNumber of shares<\/b><\/td>\nAverage purchase price (DKK)<\/b><\/td>\nTransaction value (DKK)<\/b><\/td>\n<\/tr>\n
Accumulated as per latest announcement<\/b><\/td>\n1,789,000<\/b><\/td>\n\u00a0<\/td>\n537,758,750<\/b><\/td>\n<\/tr>\n
13\/07\/2026<\/td>\n\u00a045,000<\/td>\n\u00a0281.04<\/td>\n\u00a012,646,800<\/td>\n<\/tr>\n
14\/06\/2026<\/td>\n\u00a045,000<\/td>\n\u00a0275.93<\/td>\n\u00a012,416,850<\/td>\n<\/tr>\n
15\/07\/2026<\/td>\n\u00a040,000<\/td>\n\u00a0289.88<\/td>\n\u00a011,595,200<\/td>\n<\/tr>\n
16\/07\/2026<\/td>\n\u00a035,000<\/td>\n\u00a0300.13<\/td>\n\u00a010,504,550<\/td>\n<\/tr>\n
17\/07\/2026<\/td>\n\u00a040,000<\/td>\n\u00a0289.50<\/td>\n\u00a011,580,000<\/td>\n<\/tr>\n
Accumulated (W29)<\/b><\/td>\n205,000<\/b><\/td>\n\u00a0<\/b><\/td>\n58,743,400<\/b><\/td>\n<\/tr>\n
Total accumulated under the Program<\/b><\/td>\n1,994,000<\/b><\/td>\n\u00a0<\/b><\/td>\n596,502,150<\/b><\/td>\n<\/tr>\n<\/table>\n

Treasury shares and share capital<\/b><\/p>\n

Following the transactions described above, Zealand Pharma holds a total of 2,864,482 treasury shares, corresponding to approximately 4% of the Company\u2019s share capital.<\/p>\n

The total number of shares in Zealand Pharma is 71,578,758, each with a nominal value of DKK 1.<\/p>\n

Additional information<\/b><\/p>\n

Detailed information on each transaction executed under the Program is available in the appendix to this company announcement.<\/p>\n

About Zealand Pharma<\/b>
Zealand Pharma A\/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI\/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.<\/p>\n

Contacts<\/b><\/p>\n

Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com<\/a><\/p>\n

Neshat Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com<\/a><\/p>\n

Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
Email: rjamesowens@zealandpharma.com<\/a><\/p>\n

Andreas Hylleberg M\u00f8lleskov (Media)\u00a0
Director, External Communications
Zealand Pharma
Email: ahylleberg@zealandpharma.com<\/a><\/p>\n